Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma by Arun Kanakkanthara (14937731)

Subjects:

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma by Arun Kanakkanthara (14937731)

Subjects:

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms by Dwight H. Owen (15034782)

Subjects:

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms by Dwight H. Owen (15034782)

Subjects:

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms by Dwight H. Owen (15034782)

Subjects:

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms by Dwight H. Owen (15034782)

Subjects:

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms by Dwight H. Owen (15034782)

Subjects:

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models by Elizabeth R. Tucker (15053624)

Subjects:

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models by Elizabeth R. Tucker (15053624)

Subjects:

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models by Elizabeth R. Tucker (15053624)

Subjects:

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models by Elizabeth R. Tucker (15053624)

Subjects:

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models by Elizabeth R. Tucker (15053624)

Subjects:

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models by Elizabeth R. Tucker (15053624)

Subjects:

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma by Alyssa C. Flint (16676029)

Subjects:

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma by Alyssa C. Flint (16676029)

Subjects:

Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infi... by Gregory L. Beatty (15087193)

Subjects:

Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infi... by Gregory L. Beatty (15087193)

Subjects:

Supplementary Movie S3 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling by Jesse C. Patterson (14962862)

Subjects:

Supplementary Movie S4 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling by Jesse C. Patterson (14962862)

Subjects:

Supplementary Movie S5 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling by Jesse C. Patterson (14962862)

Subjects: